The first data on international multicenter clinical study RheoSTAT-CP0691 on the efficacy and safety of Rheosorbilact® infusion in therapy of purulent peritonitis

Authors

  • S Agop Municipal Clinical Hospital, Chisinau, Moldova
  • V Sharipova Republican Scientific Center of Emergency Medical Aid, Tashkent, Uzbekistan
  • K Kashibadze Unimed Adjara” LLC — Batumi Referral Hospital, Batumi, Georgia
  • D Vashadze JSC EVEX/LTD Traumatology, Tbilisi, Georgia
  • V Tevdoradze Kutaisi Referral Hospital, Kutaisi, Georgia
  • I Kolosovich Kyiv City Clinical Hospital No.4; Bogomolets National Medical University, Kyiv, Ukraine
  • S Peev SI “Zaytsev Institute of General and Urgent Surgery of the National Academy of Medical Sciences of Ukraine” Kharkiv, Ukraine
  • A Ligonenko Poltava Central District Clinical Hospital, Poltava, Ukraine
  • V Cojocaru Republican Clinical Hospital, Chisinau, Moldova
  • A Bely Emergency Medicine Institute, Chisinau, Moldova

DOI:

https://doi.org/10.31636/prmd.v5i1.5

Keywords:

abdominal sepsis, septic shock, peritonitis, detoxification therapy, infusion therapy, efficacy, safety, Reosorbilact

Abstract

Generalized forms of peritonitis are a major factor leading to non-traumatic mortality in all cases of emergency care and the second leading cause of sepsis in critically ill patients. Objective of this study was to evaluate the efficacy and safety of multicomponent infusion solution Reosorbilact in the treatment of patients diagnosed with purulent peritonitis. An international multicenter randomized study included 181 patients aged from 18 to 60 years with a diagnosis of purulent peritonitis. Patients received therapy with Reosorbilact according to the prescribing information for use. The primary endpoint of the effectiveness was change in SOFA scale on day 3 of therapy. Changes in APACHE II, SAPS II, MODS, and MPI scores as well as changes in endogenous intoxication markers on day 3 of therapy were considered as secondary endpoints. Safety was assessed by analysis of adverse events (AE) and vital signs after 3 days of therapy. On day 3 of treatment with Reosorbilact statistically significant changes were observed in SOFA (1.80 ± 0.91 points), MODS (1.45 ± 0.76 points) and MPI (1.84 ± 5.03 points) scales. There was a statistically significant improvement in markers of endogenous intoxication (creatinine, bilirubin, white blood cell count, C-reactive protein, neutrophil to lymphocyte ratio) on day 3 of treatment. The majority of AE (98.99 %) were mild. No AE were associated with the study preparation and did not result in the patient’s withdrawal from the study. According to the results of RheoSTAT-CP0691, Rheosorbilact is an effective and safe drug for the treatment of patients with purulent peritonitis. It is advisable to include Rheosorbilact in routine treatment algorithms for patients with purulent peritonitis.

Downloads

Download data is not yet available.

References

Adesunkanmi ARK, Oseni SA, Adejuyigbe O, Agbakwuru EA. Acute generalized peritonitis in African children: assessment of severity of illness using modified APACHE II score. ANZ Journal of Surgery [Internet]. Wiley; 2003 May;73(5):275–9. Available from: https://doi.org/10.1046/j.1445-2197.2003.t01-1-02608.x

Drexel S, Tseng D. Primary Peritonitis: An Index Case of Mycoplasma hominis Infection in a Healthy Female. Case Reports in Surgery [Internet]. Hindawi Limited; 2018;2018:1–4. Available from: https://doi.org/10.1155/2018/4587801

Ghosh PS, Mukherjee R, Sarkar S, Halder SK, Dhar D. Epidemiology of secondary peritonitis: analysis of 545 cases. International journal of scientific study. 2015;2(12):83-8.

Ross JT, Matthay MA, Harris HW. Secondary peritonitis: principles of diagnosis and intervention. BMJ [Internet]. BMJ; 2018 Jun 18;k1407. Available from: https://doi.org/10.1136/bmj.k1407

Strobel O, Werner J, Büchler MW. Chirurgische Therapie der Peritonitis. Der Chirurg [Internet]. Springer Science and Business Media LLC; 2011 Mar;82(3):242–8. Available from: https://doi.org/10.1007/s00104-010-2015-2

Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, Malangoni M, Velmahos G, Coimbra R, Koike K, Leppaniemi A. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World Journal of Emergency Surgery. 2014 Dec;9(1):37.

Chichom-Mefire A, Fon TA, Ngowe-Ngowe M. Which cause of diffuse peritonitis is the deadliest in the tropics? A retrospective analysis of 305 cases from the South-West Region of Cameroon. World Journal of Emergency Surgery [Internet]. Springer Science and Business Media LLC; 2016 Apr 11;11(1):14. Available from: https://doi.org/10.1186/s13017-016-0070-9

Adesunkanmi ARK, Badmus TA. Pattern of Antibiotic Therapy and Clinical Outcome in Acute Generalized Peritonitis in Semi-Urban and Rural Nigerians. Chemotherapy [Internet]. S. Karger AG; 2006;52(2):69–72. Available from: https://doi.org/10.1159/000092370

Søreide K, Thorsen K, Søreide JA. Strategies to improve the outcome of emergency surgery for perforated peptic ulcer. British Journal of Surgery [Internet]. Oxford University Press (OUP); 2013 Nov 29;101(1):e51–e64. Available from: https://doi.org/10.1002/bjs.9368

Armstrong C. Updated guideline on diagnosis and treatment of intra-abdominal infections. American Family Physician. 2010 Sep 15;82(6).

Sartelli M, Catena F, Abu-Zidan FM, Ansaloni L, Biffl WL, Boermeester MA, Ceresoli M, Chiara O, Coccolini F, De Waele JJ, Di Saverio S. Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. World Journal of Emergency Surgery. 2017 Dec;12(1):22.

Hippensteel JA, Uchimido R, Tyler PD, Burke RC, Han X, Zhang F, et al. Intravenous fluid resuscitation is associated with septic endothelial glycocalyx degradation. Critical Care [Internet]. Springer Science and Business Media LLC; 2019 Jul 23;23(1). Available from: https://doi.org/10.1186/s13054-019-2534-2

Cordemans C, De laet Inneke, Van Regenmortel N, Schoonheydt K, Dits H, Huber W, et al. Fluid management in critically ill patients: the role of extravascular lung water, abdominal hypertension, capillary leak, and fluid balance. Annals of Intensive Care [Internet]. Springer Science and Business Media LLC; 2012 Jul 5;2(S1). Available from: https://doi.org/10.1186/2110-5820-2-s1-s1

Malbrain MLNG, Marik PE, Witters I, Cordemans C, Kirkpatrick AW, Roberts DJ, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anestezjologia Intensywna Terapia [Internet]. Termedia Sp. z.o.o.; 2014 Nov 28;46(5):361–80. Available from: https://doi.org/10.5603/ait.2014.0060

Heung M, Wolfgram DF, Kommareddi M, Hu Y, Song PX, Ojo AO. Fluid overload at initiation of renal replacement therapy is associated with lack of renal recovery in patients with acute kidney injury. Nephrology Dialysis Transplantation [Internet]. Oxford University Press (OUP); 2011 Aug 19;27(3):956–61. Available from: https://doi.org/10.1093/ndt/gfr470

Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney International [Internet]. Elsevier BV; 2009 Aug;76(4):422–7. Available from: https://doi.org/10.1038/ki.2009.159

Stein A, de Souza L, Belettini C, Menegazzo W, Viégas J, Costa Pereira E, et al. Fluid overload and changes in serum creatinine after cardiac surgery: predictors of mortality and longer intensive care stay. A prospective cohort study. Critical Care [Internet]. Springer Science and Business Media LLC; 2012;16(3):R99. Available from: https://doi.org/10.1186/cc11368

Best MW, Jabaley CS. Fluid Management in Septic Shock: a Review of Physiology, Goal-Directed Therapy, Fluid Dose, and Selection. Current Anesthesiology Reports [Internet]. Springer Science and Business Media LLC; 2019 Apr 22;9(2):151–7. Available from: https://doi.org/10.1007/s40140-019-00330-3

Marik P, Bellomo R. A rational approach to fluid therapy in sepsis. British Journal of Anaesthesia [Internet]. Elsevier BV; 2016 Mar;116(3):339. Available from: https://doi.org/10.1093/bja/aev349

Hahn RG, Lyons G. The half-life of infusion fluids. European Journal of Anaesthesiology [Internet]. Ovid Technologies (Wolters Kluwer Health); 2016 Jul;33(7):475–82. Available from: https://doi.org/10.1097/eja.0000000000000436

Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. Albumin Replacement in Patients with Severe Sepsis or Septic Shock. New England Journal of Medicine [Internet]. Massachusetts Medical Society; 2014 Apr 10;370(15):1412–21. Available from: https://doi.org/10.1056/nejmoa1305727

A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit. New England Journal of Medicine [Internet]. Massachusetts Medical Society; 2004 May 27;350(22):2247–56. Available from: https://doi.org/10.1056/nejmoa040232

Saline or Albumin for Fluid Resuscitation in Patients with Traumatic Brain Injury. New England Journal of Medicine [Internet]. Massachusetts Medical Society; 2007 Aug 30;357(9):874–84. Available from: https://doi.org/10.1056/nejmoa067514

Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. New England Journal of Medicine [Internet]. Massachusetts Medical Society; 2012 Nov 15;367(20):1901–11. Available from: https://doi.org/10.1056/nejmoa1209759

Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. New England Journal of Medicine. 2012 Jul 12;367(2):124-34. Available from: https://doi.org/10.1056/nejmoa1204242

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit. Care Med. 2017;45(3):486–552.

MacDonald N, Pearse RM. Are we close to the ideal intravenous fluid? British Journal of Anaesthesia [Internet]. Elsevier BV; 2017 Dec;119:i63–i71. Available from: https://doi.org/10.1093/bja/aex293

Magee CA, Bastin MLT, Laine ME, Bissell BD, Howington GT, Moran PR, et al. Insidious Harm of Medication Diluents as a Contributor to Cumulative Volume and Hyperchloremia. Critical Care Medicine [Internet]. Ovid Technologies (Wolters Kluwer Health); 2018 Aug;46(8):1217–23. Available from: https://doi.org/10.1097/ccm.0000000000003191

Self WH, Semler MW, Wanderer JP, Wang L, Byrne DW, Collins SP, et al. Balanced Crystalloids versus Saline in Noncritically Ill Adults. New England Journal of Medicine [Internet]. Massachusetts Medical Society; 2018 Mar;378(9):819–28. Available from: https://doi.org/10.1056/nejmoa1711586

Self WH, Semler MW, Wanderer JP, Wang L, Byrne DW, Collins SP, et al. Balanced Crystalloids versus Saline in Noncritically Ill Adults. New England Journal of Medicine [Internet]. Massachusetts Medical Society; 2018 Mar;378(9):829–39. Available from: https://doi.org/10.1056/nejmoa1711586

Dalton C. Why did sterile salt water become the IV fluid of choice? NPR. 2018.

Kondratsky BA, Novak VL. Experience in the use of the complex infusion drug rheosorbilact in clinical practice [Opyt primeneniya v klinicheskoy praktike kompleksnogo infuzion nogo preparata reosorbilakt]. Mystic face bath. 2006;1:34-6. [In Russian]

Khamidov DB, Kosimov ZK, Homidov DD, Kiyamov SE. Complex polyfunctional solution of rheosorbilact in intensive therapy of endogenous intoxication in patients with acute peritonitis [Kompleksnyy polifunktsional'nyy rastvor reosorbilakt v intensivnoy terapii endogennoy intoksikatsii u bol'nykh s ostrym peritonitom]. Scientific and practical journal TIPPMK. 2011(2):77-9. [In Russian]

Aliev NA, Bobiev AB, Khamidov DB, Barotov ED, Buriev TN, Kurbanov DA, Shomurodov Kh, Eshmirzaev BA. Rheosorbilact and Latren in the correction of endogenous intoxication and oxidative stress in patients with acute destructive pancreatitis [Reosorbilakt i Latren v korrektsii endogennoy intoksikatsii i oksidantnogo stressa u bol'nykh s ostrym destruktivnym pankreatitom]. Emergency medicine. 2015;1(64):57-9. [In Russian]

Pronichev VV, Styazhkina SN, Mikhailov AYu. Efficiency of treatment with rheosorbilact in patients with diabetic foot syndrome [Effektivnost' lecheniya reosorbilaktom patsiyentov s sindromom diabeticheskoy stopy]. Health, demography, ecology of the Finno-Ugric peoples. 2016;2:30-2. [In Russian]

Rizhko OO. Reosorbilact infusion therapy [Infuziyna terapiya Reosorbilaktom]. Ukrainian Pulmonology Journal. 2002;1:94-6. [In Ukraine]

Перші дані про результати міжнародного багатоцентрового клінічного дослідження RheoSTAT-CP0691 щодо ефективності та безпеки інфузійного розчину Реосорбілакт® у комплексній терапії гнійного перитоніту

Published

2022-05-30

How to Cite

1.
Agop S, Sharipova V, Kashibadze K, Vashadze D, Tevdoradze V, Kolosovich I, Peev S, Ligonenko A, Cojocaru V, Bely A. The first data on international multicenter clinical study RheoSTAT-CP0691 on the efficacy and safety of Rheosorbilact® infusion in therapy of purulent peritonitis. prmd [Internet]. 2022 May 30 [cited 2022 Sep. 30];5(1):34-46. Available from: https://perioperative.org.ua/index.php/prtmdc/article/view/103

Issue

Section

Original article